COMMUNIQUÉS West-GlobeNewswire

ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update

16/05/2018 - 13:01

-Key First Quarter 2018 Clinical Milestones Achieved Patient randomization completed in Phase 2b EDELWEISS trial of OBE2109 in Endometriosis, results expected by the end of Q2:18, and Primary endpoint achieved in Phase [...]

Evolus to Provide Regulatory Update on Wednesday, May 16, 2018

16/05/2018 - 13:01

IRVINE, Calif., May 16, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS ) (“Evolus”), a lifestyle aesthetics company focused on delivering advanced aesthetic procedures and treatments to physicians and consumers, [...]

Aclaris Therapeutics Announces Poster Presentations at International Investigative Dermatology 2018 Meeting

16/05/2018 - 13:00

WAYNE, Pa., May 16, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS ), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to [...]

EyePoint Pharmaceuticals Announces Appointment of Leonard Blum as Executive Vice President and General Manager, U.S.

16/05/2018 - 13:00

WATERTOWN, Mass., May 16, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT ), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today [...]

ESPERITE NV (ESP) WITH CRYOSAVE TAKES OVER FULL CONTROL OF BUSINESS IN SOUTH AFRICA AND INTEND TO DISTRIBUTE ADVANCED SERVICES TO THE GROWING AFRICAN POPULATION

16/05/2018 - 09:32

Amsterdam, the Netherlands - 16 May 2018 Esperite NV, The Regenerative and predictive medicine company has acquired control of its long-term South African joint venture CryoSave South Africa Ltd. Effective 1 April 2018 [...]

LIDDS: Delårsrapport januari-mars 2018

16/05/2018 - 08:31

FÖRSTA KVARTALET: JANUARI - MARS 2018 Nettoomsättningen uppgick till 0,0 (0,0) KSEK Kostnaderna uppgick till 2,0 (1,8) MSEK Resultatet före och efter skatt uppgick till -2,0 (-1,8) MSEK Resultat per aktie uppgick till - [...]

Terveystalo Plc: Terveystalo Group Interim Report January 1 - March 31, 2018

16/05/2018 - 08:01

Terveystalo Plc Interim report 16 May 2018 at at 9:00 a.m. EEST CONTINUOUS SALES AND EARNINGS GROWTH Highlights of the review period January-March 2018 Revenue increased by 23 per cent year-on-year to EUR 197.5 million [...]

Kiadis Pharma to Present at Upcoming Investor Conferences

16/05/2018 - 08:01

Kiadis Pharma to Present at Upcoming Investor Conferences Amsterdam, The Netherlands, May 16, 2018 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS ), a clinical stage [...]

Shire plc: Rule 2.9 Announcement

16/05/2018 - 08:01

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 16 May 2018 Shire [...]

DBV Technologies Announces Appointment of Michel de Rosen to its Board of Directors

16/05/2018 - 07:31

Montrouge, France, May 16, 2018 DBV Technologies Announces Appointment of Michel de Rosen to its Board of Directors DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage [...]

DBV Technologies annonce la nomination de Michel de Rosen à son Conseil d'administration

16/05/2018 - 07:31

Montrouge, France, le 16 mai (07h30 CEST) 2018 DBV Technologies annonce la nomination de Michel de Rosen à son Conseil d'administration DBV Technologies (Euronext : DBV - ISIN : FR0010417345 - Nasdaq : DBVT), société [...]

At the Meet Novartis Management investor event, Novartis highlights strategy to focus the company and drive sustainable growth

16/05/2018 - 07:16

Full pipeline of late stage assets with blockbuster potential Positioned to deliver sales growth and margin expansion through 2022 Pipeline depth in key therapeutic areas and building new, distinctive platform [...]

Sanofi: Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis

16/05/2018 - 07:01

Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis U.S. regulatory submission [...]

Sanofi : Résultats positifs de phase III pour Dupixent® (dupilumab) dans le traitement de la dermatite atopique modérée à sévère inadéquatement contrôlée de l'adolescent

16/05/2018 - 07:01

Communiqué de presse Source : Sanofi (EURONEXT: SAN) (NYSE: SNY) Résultats positifs de phase III pour Dupixent ® (dupilumab) dans le traitement de la dermatite atopique modérée à sévère inadéquatement contrôlée de l' [...]

INNATE PHARMA : First quarter 2018 report

16/05/2018 - 07:01

first quarter 2018 report Cash, cash equivalents and financial assets of the Company amounted to €153.8 million [*] Significant momentum across the portfolio, with good progress on the joint monalizumab program with [...]

INNATE PHARMA : Information financière du premier trimestre 2018

16/05/2018 - 07:01

Information financiÈre du premier trimestre 2018 Trésorerie, équivalents de trésorerie et actifs financiers s'élevant à 153,8 millions d'euros [*] Progrès significatifs dans le portefeuille notamment pour monalizumab [...]

Idorsia initiates MODIFY, a Phase 3 registration study to assess lucerastat as a potential new treatment option for patients with Fabry disease

16/05/2018 - 07:01

Idorsia to host an investor webcast to discuss the Phase 3 program today at 14:00hrs CEST Allschwil, Switzerland - May 16, 2018 Idorsia Ltd (SIX: IDIA) today announced that the first patient has been enrolled in a [...]

Novartis announces changes to the Executive Committee

16/05/2018 - 07:01

Felix R. Ehrat, Group General Counsel, will retire on June 1, 2018 Shannon Thyme Klinger appointed to Group General Counsel Robert Weltevreden appointed Head of Novartis Business Services Basel, May 16, 2018 - Novartis [...]

Targovax to present at upcoming investor and industry conferences

16/05/2018 - 07:01

Oslo, Norway, 16 May 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that members of its senior management will present at the [...]